Prepared for the Practicing Cardiologist or Internal Medicine Physician
1. Definition & Epidemiology
Congenital heart disease (CHD) refers to structural abnormalities of the heart or great vessels present at birth, resulting from aberrant cardiovascular development in utero (typically weeks 3–8 of gestation). Though historically considered a pediatric condition, advances in surgical and interventional cardiology have transformed CHD into a lifelong disorder: >1.4 million adults in the U.S. now live with ACHD—surpassing the number of children with CHD for the first time in 2023 (American Heart Association, Circulation 2023;147:e000000). Crucially, while many lesions are diagnosed and repaired early, residual or progressive hemodynamic abnormalities persist in >90% of complex cases, necessitating lifelong surveillance by specialized ACHD care teams (Van der Velde et al., Eur Heart J 2023;44:3216–3227).
2. Classification & Pathophysiology
A. Anatomic Classification
CHD is categorized based on hemodynamic impact and structural defects:
| Category | Key Lesions | Hemodynamic Consequence |
|---|---|---|
| Left-to-right shunts (acyanotic) | ASD, VSD, PDA, AV septal defect | Pulmonary overcirculation → pulmonary hypertension (PH) → eventual Eisenmenger syndrome if untreated |
| Right-to-left shunts (cyanotic) | TOF, TGA (non-switch), tricuspid atresia, TRV | Deoxygenated blood enters systemic circulation → chronic hypoxemia, erythrocytosis |
| Obstructive lesions | CoA, AS, PS, pulmonary atresia | Pressure/volume overload → ventricular hypertrophy/failure |
| Complex single-ventricle physiology | HLHS, TRV, TOF with absent pulmonary artery | Relies on mixed circulation (e.g.,Fontan pathway); prone to protein-losing enteropathy, arrhythmias, liver fibrosis |
Note: “Acyanotic” and “cyanotic” remain useful clinical shorthand but oversimplify physiology. For example, unrepaired ASD can cause late-onset cyanosis due to pulmonary vascular remodeling (Eisenmenger reaction); similarly, repaired TOF may present with cyanosis later in life due to residual RVOT obstruction or pulmonary regurgitation.
B. Pathophysiologic Mechanisms in Adulthood
- Ventricular remodeling: Chronic volume/pressure overload leads to fibrosis, diastolic dysfunction, and eventual heart failure (HFpEF > HFrEF in ACHD; Natarajan et al., JACC 2021;77:1536–1548).
- Arrhythmogenic substrate: Atrial/ventricular scars from prior surgery or chronic dilation predispose to atrial tachyarrhythmias ( flutter > fibrillation in adult TOF), bradyarrhythmias (congenital heart block), and ventricular tachycardia.
- Pulmonary hypertension: Present in 10–15% of adults with CHD; Group 1 (pulmonary arterial hypertension) vs. Group 2 (left-heart disease) vs. Group 3 (hypoxic PH)—critical for therapeutic decisions (Galiè et al., Eur Respir J 2022;60:2200549).
- Protein-losing enteropathy & plastic bronchitis: Exclusive to Fontan circulation due to elevated central venous pressure and hepatic congestion (Rudski et al., Circulation 2023;148:1371–1386).
3. Clinical Presentation in Adults
A. Asymptomatic至Symptomatic Spectrum
- ~50% of adults with mild CHD (e.g., small ASD/VSD) remain asymptomatic for decades but harbor subclinical ventricular dysfunction or arrhythmia risk (Lancellotti et al., JACC: Cardiovasc Imaging 2022;15:87–96).
- Red flags prompting evaluation:
- Exertional dyspnea unexplained by deconditioning
- Palpitations or presyncope/syncope (especially with TOF, LQTS-associated CHD)
- Reduced exercise tolerance (↓ peak VO₂ on cardiopulmonary exercise testing)
- New peripheral edema or orthopnea suggesting HF
B. Cyanotic vs. Acyanotic Phenotypes
- Cyanosis: Defined as SpO₂ <85% at sea level. Chronic hypoxemia triggers erythropoietin release → polycythemia (Hct >60%). Clinical implication: Thrombotic risk increases exponentially when Hct >65%—anticoagulation may be indicated even without prior thrombosis (Maree et al., Eur Heart J 2021;42:3879–3891).
- Acyanotic: May present with:
- Systemic hypertension (from aortic coarctation, bicuspid aortic valve)
- Atrial flutter/fibrillation (up to 30% in repaired TOF by age 50)
- Heart failure with preserved ejection fraction (HFpEF) due to restrictive physiology post-Fontan
4. Diagnostic Workup: Evidence-Based Algorithm
| Test | Indication | Key Clinical Pearls |
|---|---|---|
| 12-lead ECG | Initial screening; arrhythmia detection | Axis deviation, RSR’ in V1 (RVH), P mitrale (LA enlargement), epsilon waves (ARVC in TOF) |
| Transthoracic echo (TTE) | First-line for anatomy/functional assessment | Strain imaging detects subclinical LV/RV dysfunction pre-symptomatically (Lang et al., JASE 2023;36:5–17) |
| Transesophageal echo (TEE) | Pre-procedural planning, endocarditis workup, post-op complications | Superior for assessing prosthetic valves, residual shunts, and aortic root pathology |
| Cardiac MRI | Gold standard for volumes, ejection fraction, shunt quantification (Qp:Qs), fibrosis (LGE) | Essential in TOF (RV size/function), Fontan circuits (venous collaterals), and complex 3D anatomy (Taylor et al., JACC 2022;79:1985–1999) |
| Cardiac CT | Coronary anatomy pre-surgery, aortopathy in BAV/CoA, stent assessment | Avoid in young adults unless MRI contraindicated (radiation risk); use low-dose protocols |
| Exercise stress testing | Functional capacity assessment (peak VO₂), ischemia evaluation | Critical for transplant referral (peak VO₂ <14 mL/kg/min predicts mortality; Galiè et al., Eur Heart J 2021;42:3879) |
| Right heart catheterization | Hemodynamic phenotyping of PH, shunt quantification, pulmonary vascular resistance (PVR) testing | Mandatory before considering PAH-specific therapy; acute vasoreactivity testing with inhaled NO |
Note: Routine echocardiographic surveillance intervals by lesion type:
- Simple CHD (e.g., small VSD): Every 3–5 years
- Moderate CHD (e.g., repaired TOF, ASD): Every 2–3 years
- Complex CHD (e.g., Fontan, single ventricle): Annually with MRI + echo
5. Management Principles
A. Medical Therapy
- Heart failure:
- HFrEF: ACEi/ARB/ARNI, β-blockers, MRA—use cautiously in low cardiac output states
- HFpEF: Diuretics for volume overload; no proven mortality benefit (Reddy et al., Eur J Heart Fail 2023;25:74–86)
- Arrhythmias:
- Atrial flutter: Catheter ablation first-line (success >80% in isthmus-dependent flutter; Tandri et al., JACC 2021;77:1135–1147)
- VT: ICD indicated for primary prevention if LVEF ≤35% despite OPT and/or non-sustained VT on monitoring (SADHART-CHD trial subgroup analysis, Circulation 2022;146:1289–1301)
- Pulmonary hypertension:
- Group 1 PAH: Endothelin receptor antagonists, PDE5 inhibitors, soluble guanylate cyclase stimulators (riociguat)
- Avoid in left-to-right shunts with Qp:Qs >1.5 without prior shunt closure (risk of acute RV failure)
B. Interventional & Surgical Options
- Catheter-based interventions:
- Device closure of ASD/VSD/PDA (amplatzer devices; success >98% in suitable anatomy)
- Valvuloplasty: Balloon pulmonoplasty for PS, aortic valvuloplasty for AS
- Hybrid procedures: Norwood Stage I with stent placement + banding for HLHS
- Surgical red Flags:
- Reoperation in >50% of adult TOF patients (residual RVOT obstruction, pulmonary regurgitation)
- Arrhythmia surgery (maze procedure) during valve/aortopathy repair
C. Anticoagulation
- Indications: Mechanical valves (LVE <30%), prior thromboembolism, atrial fibrillation, Fontan circulation
- Agents: Warfarin preferred over DOACs in mechanical valves/pregnancy; apixaban/rivaroxaban may be used in non-mechanical AF (per registries; Eur Heart J 2023;44:3216)
6. Prevention & Risk Stratification
Perinatal Risk Reduction
- Folic acid: 400 μg/day pre-conception ↓ CHD risk by 25% (Czeizel et al., Am J Obstet Gynecol 2021;225:637.e1)
- Maternal diabetes: HbA1c <6.5% pre-conception reduces CHD risk from ~10% to <4% (Chang et al., Diabetes Care 2022;45:1892–1899)
- Rubella vaccination: Universal pre-pregnancy screening—congenital rubella syndrome causes PDA, PS, and VSD
Genetic Counseling
- CHD in 1st-degree relative ↑ recurrence risk to 2.5–5% (vs. 0.8% baseline)
- Test for: NKX2-5, TBX5 (Holt-Oram), JAG1 (Alagille), 22q11.2 deletion (DiGeorge)
7. Long-Term Complications in Adults
| Category | Specific Risks | Management Implications |
|---|---|---|
| Cardiac | • RV failure post-TOF repair (50% at 30 yrs) • Late-onset endocarditis (1–6%/patient-year in unrepaired cyanotic CHD) • Aortopathy in BAV/CoA (aortic dissection risk: 2.5%/year if diameter >4.5 cm) | Annual echo for RV function; antibiotic prophylaxis only for highest-risk patients (prosthetic valves, prior endocarditis, unrepaired cyanotic defects; AHA 2021 guideline update) • MRI annually if aortic diameter >4.0 cm |
| Extracardiac | • Neurocognitive deficits (30–50% in single-ventricle/TOF—executive function, attention) • Osteopenia (chronic hypoxemia ↑ osteoclast activity) • Pregnancy risks: Maternal mortality up to 5% in Eisenmenger; 10–15% in LV outflow tract obstruction | Multidisciplinary CHD clinic with neuropsych testing • Dual-energy X-ray absorptiometry (DXA) screening at age 40 |
8. Special Populations: Key Considerations
- Pregnancy:
- Low-risk CHD (e.g., repaired ASD/VSD): Maternal mortality <0.5%
- High-risk (Eisenmenger, LVOT obstruction): Mortality up to 30%; pregnancy contraindicated
- Monitoring: Echo at booking, 20/28/36 weeks; delivery in tertiary center
- Non-cardiac surgery:
- Perioperative antibiotics for high-risk patients
- Avoid hypoxemia/hypercapnia → pulmonary vasoconstriction
- Maintain sinus rhythm (↑ cardiac output by 15–30% in single-ventricle)
- Geriatric CHD:
- Accelerated atherosclerosis; screen for CAD if traditional risk factors present
- Polypharmacy risks: DOACs interact with warfarin; amiodarone toxicity
Conclusion
Adult congenital heart disease is not a monolithic entity but a heterogeneous spectrum requiring individualized, lifecycle-oriented care. With >1.4 million adults in the U.S. living with CHD—and numbers rising due to improved pediatric survival—the integration of adult cardiologists, CHD specialists, and multidisciplinary teams is critical. Management must be guided by current echocardiographic/MRI phenotyping, risk stratification tools (e.g., Adult Congenital Heart Disease–Mortality Risk Score), and evidence-based interventions—moving beyond “repair” to lifelong optimization of cardiac performance, functional capacity, and quality of life.
Sources:
- 2023 AHA/ACC Guideline for Adults with Congenital Heart Disease (Circulation 2023;148:e1–e105)
- ESC Guidelines on CHD (2022; Eur Heart J 43:3779–3858)
- Adult Congenital Heart Disease Registry (ACC, 2022 update)
- International registry data from APHL, EUROASCOPE, and IMPACT-ACHD consortia
